- Home
- EOS vs MDXG Comparison
EOS vs MDXG Comparison
Compare EOS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOS | MDXG |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EOS | MDXG |
|---|---|---|
| Price | $21.27 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 107.6K | ★ 775.6K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | ★ N/A | $13.69 |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $17.56 | $4.34 |
| 52 Week High | $24.49 | $8.13 |
Technical Indicators
Market Signals| Indicator | EOS | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 29.39 |
| Support Level | $21.17 | N/A |
| Resistance Level | $24.40 | $5.38 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 14.08 | 7.41 |
Price Performance
Historical ComparisonAbout EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.